There are 3163 resources available
50P - Camrelizumab (Cam) combined with gemcitabine and cisplatin (GP) plus low-dose apatinib in first-line treatment of advanced biliary tract cancer (BTC)
Presenter: yunxin lu
Session: Poster session 13
52P - Cadonilimab in combined with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): A phase II, single-arm clinical trial
Presenter: Ji Ma
Session: Poster session 13
54P - BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic biliary tract carcinoma (BTC)
Presenter: Zhihao Lu
Session: Poster session 13
55P - Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)
Presenter: Arndt Vogel
Session: Poster session 13
56P - Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study
Presenter: Federico Nichetti
Session: Poster session 13
57P - Integrative analysis of the genomic and transcriptomic landscape identifies ciliary genes as a therapeutic target in bile duct cancer
Presenter: Pietro Carotenuto
Session: Poster session 13
58P - Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials
Presenter: Changhoon Yoo
Session: Poster session 13
59P - Prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: Results from the French prospective FFCD cohort
Presenter: Gael Roth
Session: Poster session 13